-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis announced on August 25 that the China Drug Administration has approved a combination of radioligand therapy drug Pavital® and an androgen receptor pathway inhibitor to treat prostate-specific membrane antigen-positive metastatic hormone-sensitive prostate cancer.

Zhitongcaijing·08/25/2026 13:49:08
Listen to the news
Novartis announced on August 25 that the China Drug Administration has approved a combination of radioligand therapy drug Pavital® and an androgen receptor pathway inhibitor to treat prostate-specific membrane antigen-positive metastatic hormone-sensitive prostate cancer.